乌拉坦诱导的高血糖反应(英文)

目的:观察麻醉剂量的乌拉坦对空腹大鼠、葡萄糖负荷大鼠,肾上腺素或四氧嘧啶诱发高血糖大鼠血糖水平的影响,并探讨其对外源性胰岛素降血糖作用的影响。方法:葡萄糖氧化酶法测定血糖含量。结果:麻醉剂量1.5g·kg~(-1)乌拉坦(sc,ip各半)显著升高空腹大鼠和葡萄糖负荷大鼠的血糖水平,但对肾上腺素(胰岛功能正常)或四氧嘧啶(胰岛功能受损)诱发的高血糖大鼠的血糖水平无明显影响。在四氧嘧啶诱发的高血糖大鼠,乌拉坦显著对抗外源性胰岛素的降血糖作用。结论:乌拉坦升高血糖的作用除与已知的释放肾上腺素有关外,抑制胰岛素的降血糖作用也是其升高血糖的机制之一。     

地尔硫对大鼠胰岛素水平的影响

目的　观察钙拮抗剂地尔硫 (Dil)对空腹大鼠、葡萄糖负荷大鼠以及肾上腺素诱发高血糖大鼠血浆胰岛素水平的影响。方法　采用放射免疫测定法测定血浆胰岛素含量。结果　空腹大鼠灌胃给予 10mg·kg-1和 10 0mg·kg-1Dil后 ,胰岛素水平升高 ;与对照组相比 ,Dil 10 0mg·kg-1给药后 30min使胰岛素水平增加了 1 31倍。在糖耐量试验中 ,Dil两剂量均升高胰岛素水平。在肾上腺素诱发高血糖大鼠 ,Dil 10 0mg·kg-1仅在给药后 1h轻度升高血浆胰岛素水平。结论　Dil升高空腹大鼠和葡萄糖负荷大鼠血浆胰岛素水平 ,该作用除与药物诱发的血糖升高有关外 ,可能也与Dil的某些尚未发现的作用有关。     

格列美脲与格列本脲治疗2型糖尿病比较

目的 :研究格列美脲治疗 2型糖尿病的疗效、不良反应及对胰岛素分泌的影响。方法 :6 7例 2型糖尿病分为 2组 ,格列美脲组 33例 ,初始剂量为1mg ,po ,qd ;格列本脲组 34例 ,初始剂量为2 .5mg ,po ,qd ;2组均根据血糖调整剂量 ,服药 12wk后测定血糖、胰岛素、糖化血红蛋白 (HbA1c)等变化。结果 :12wk治疗后格列美脲组空腹血糖、餐后 2h血糖和HbA1c值明显下降 [(2 .5±s 0 .4 )mmol·L- 1,(3.72± 0 .0 6 )mmol·L- 1和 (1.5 7±0 .0 5 ) % ,均P <0 .0 1];空腹胰岛素水平升高值无明显变化 [(0 .8± 0 .4 )mU·L- 1,P >0 .0 5 ];餐后 2h胰岛素水平明显升高 [(13.5± 2 .2 )mU·L- 1,P <0 .0 1],与格列本脲组比较差异均无显著意义 (P >0 .0 5 )。但格列本脲组餐后 2h胰岛素水平变化明显高于格列美脲组 [(37± 4 )mU·L- 1vs (34± 4 )mU·L- 1,P <0 .0 1) ]。结论 :格列美脲是一种安全有效的降糖药 ,较格列本脲有更强的胰外降糖作用     

不同区段的胃肠转流术对2型糖尿病大鼠的治疗效果及胰岛素抵抗的影响

目的 探讨胃转流手术对2型糖尿病大鼠(GK大鼠)的治疗效果及手术后大鼠空腹血糖的变化与胰岛素、胰岛血糖素样肽(GLP-1)的分泌以及胰岛素抵抗作用的相关性.方法 运用抽签法将32只GK大鼠随机分成四组(n=8),实施保留全胃、不同区段小肠转流的胃肠转流术(GBP)建立起GK大鼠手术动物模型,分别为:对照组;十二指肠转流组;空肠转流组;回肠转流组.分别于术前第1周及术后第1、3、6、12周采取所有大鼠眼眶后静脉血,动态测定各只大鼠体质量和血液中空腹血糖值;应用酶联免疫吸附试验检测各组大鼠手术前后血清胰岛素、GLP-1的水平,最后计算出各只大鼠胰岛素抵抗指数(HOMA-IR).结果 (1)全组32只大鼠的手术成功率为90%,回肠转流组大鼠术后3~4 周时由于严重营养不良相继死亡;(2)与术前和同时间点对照组相比,GBP手术组术后空腹血糖水平均下降,至术后12周时十二指肠转流组由(14.98±2.17)mmol·L-1下降至(5.23±0.70)mmol·L-1(P<0.05);空肠转流组由(15.20±1.92)mmol·L-1下降至(5.29±0.42)mmol·L-1(P<0.05),且比十二指肠转流组降低较显著;(3)与术前相比,术后除回肠转流组外其余各组GK大鼠的体质量均增加,回肠转流组大鼠体质量术后显著降低(P<0.05);(4)与术前和同时间点对照组相比,GBP手术组术后空腹胰岛素先升高后降低,至术后12周时比术前减少;十二指肠转流组由(14.86±1.22) mU·L-1下降至(9.46±1.10) mU·L-1(P<0.05);空肠转流组由(14.71±1.14) mU·L-1下降至(8.93±1.36) mU·L-1(P<0.05) ,且比十二指肠转流组下降尤为显著;(5)与术前和同时间点对照组相比,GBP手术组术后GLP-1水平均有不同幅度的升高,至12周时达到最高,十二指肠转流组由(9.38±1.88)升高至(18.96±3.42)(P<0.05);空肠转流组由(9.02±2.20)升高至(23.23±4.17)(P<0.05) ,且比十二指肠转流组上升较为明显;(6)与术前和同时间点对照组相比,GBP手术组术后大鼠HOMA-IR均下降,至12周时下降明显;十二指肠转流组由(9.97±1.95)下降至(2.21±0.38)(P<0.05);空肠转流组由(9.98±1.39)下降至(2.03±0.23)(P<0.05) ,且比十二指肠转流组下降略为明显.结论 保留全胃的胃肠转流手术对非肥胖型GK大鼠有明显的治疗效果,且与大鼠的体质量增减无关;GBP的最佳转流效应区域可能是小肠中段,即空肠与回肠交界处;术后食物提前进入末端回肠,刺激GLP-1的分泌增多,从而达到GBP对2型糖尿病的治疗作用.     

米力农诱导的胰岛素抵抗对大鼠糖脂代谢的影响

目的　探讨选择性磷酸二酯酶Ⅲ (PhosphdiesteraseⅢ ,PDE3)抑制剂米力农 (milrinone)对大鼠胰岛素分泌、血糖、血浆游离脂肪酸 (freefattyacid ,FFA)的影响和剂量依赖关系 ,及其在胰岛素钳夹状态下对大鼠糖代谢和胰岛素敏感性的影响。方法　由植入导管给予大鼠不同剂量的米力农 ( 1,5 ,2 5 μmoL·kg- 1 )在不同时相测定血糖、血浆FFA和胰岛素水平并与对照组比较。在意识清醒状态下建立大鼠高胰岛素 正常血糖钳夹技术 ,并在钳夹 12 0min时分别经导管给予米力农 ( 2 5 μmoL·kg- 1 )和 2 5 %二甲基亚砜 (DMSO ,对照组 )。采用气相色谱 -质谱仪 (GC MS)测定糖代谢率。结果　 3个不同剂量米力农组血浆FFA浓度明显高于对照组和给药前 ,在注射后 2min ,各组FFA升高的百分数为 :5 0 %、5 2 %、5 5 % ( 1,5 ,2 5 μmoL·kg- 1 )。在 ( 5 ,2 5 )μmoL·kg- 1 组血浆胰岛素水平也明显高于对照组和给药前 ,仅 2 5 μmoL·kg- 1 组血糖浓度高于对照组和给药前。在胰岛素钳夹研究中 ,米力农处理组大鼠血浆FFA明显高于给药前 ( 173± 15vs 6 34± 87μmoL·kg- 1 ) ,肝糖输出 (HGP)也明显高于给药前( - 5 1± 3 1vs 7 5± 2 0mg·kg- 1 ·min)。葡萄糖输注率 (Glucoseinfusionrate,GIR)明显低于对照组和给药前 (     

硝苯地平控释片对老年高血压病人胰岛素抵抗的影响

目的 :了解硝苯地平控释片对老年高血压病人的胰岛素抵抗 (IR)的影响。方法 :60例老年高血压病人 (男性 45例 ,女性 1 5例 ,年龄 74a±s 5a) ,每日早餐后口服硝苯地平控释片 3 0～ 60mg,连续服用 8wk。于治疗前后测血压 ,空腹及餐后 2h血糖(BG) ,血胰岛素 (IS) ,计算出胰岛素敏感指数(ISI)。结果 :服药 8wk后 ,收缩压下降了 5 .0kPa± 2 .1kPa,舒张压下降了 4.9kPa± 1 .8kPa(均P<0 .0 1 ) ,空腹及餐后 2hIS下降分别为 5mU·L-1± 7mU·L-1(P <0 .0 1 ) ,6mU·L-1± 3 4mU·L-1(P >0 .0 5 ) ,ISI治疗后下降了 0 .3± 0 .4(P <0 .0 1 )。结论 :硝苯地平控释片治疗老年高血压病人不仅降压效果确切 ,而且能改善病人的IR。     

重组人胰高血糖素样肽-1对实验性糖尿病大鼠血糖的影响

目的观察重组人胰高血糖素样肽 1[rhGLP 1(7 36 )NH2 和rhGLP 1(7 37) ]对实验性糖尿病大鼠模型血糖和血浆胰岛素水平的影响。方法正常SD大鼠按 3.2 4g/kg腹腔注射 5 0 %葡萄糖 ,诱发暂时性高血糖动物模型。腹腔注射不同剂量 (2 0、4 0、80 μg/kg)rhGLP 1(7 36 )NH2 和rhGLP 1(7 37) ,间隔取血测定血糖与血浆胰岛素水平。正常SD大鼠按 6 0mg/kg腹腔注射链脲佐菌素 ,建立实验性 1型糖尿病大鼠模型。静脉输注rhGLP 1(7 36 )NH2 [4.0ng/(kg·min) ]12 0min并观察血糖变化。结果腹腔注射 4 0、80 μg/kgrhGLP 1(7 36 )NH2 和rhGLP 1(7 37)处理组大鼠的血糖、血浆胰岛素水平与对照组之间的差别具有非常显著性意义 (P <0 .0 0 1) ,且呈现一定的量效关系。二者之间促胰岛素分泌和降血糖活性差异无显著性。静脉输注rhGLP 1(7 36 )NH2 6 0min后 ,血糖水平 (17.0 4± 1.31)mmol/L(P <0 .0 5 ) ,12 0min后血糖水平 (11.98± 1.0 5 )mmol/L(P <0 .0 0 1)。结论rhGLP 1能显著改善实验性糖尿病大鼠的血糖水平 ,这与其促胰岛素分泌活性有关。     

重组甘精胰岛素注射液连续给药不同时间在犬体内的药动学研究

目的:研究重组甘精胰岛素注射液连续给药不同时间在犬体内的药动学。方法:采用125I胰岛素放射免疫分析药盒测定犬血中胰岛素水平。取犬随机分为高、中、低剂量(0·26、0·13、0·065mg·kg-1)组,每组6只,皮下注射相应重组甘精胰岛素,每日1次,连续给药12周,分别测定给药6、12周末各组犬血中胰岛素水平,并用3p97软件计算药动学参数。结果:胰岛素检测浓度线性范围为40～1280mU·L-1(r=0·9917),最低定量限为40mU·L-1,平均相对回收率为(96·34±4·91)%,RSD均<12·0%。犬血中重组甘精胰岛素的药动学参数分别为给药6周末的t1/2α:(0·89±0·40)～(1·43±1·01)h,cssmax:(2·30±1·16)～(11·69±4·26)mU·mL-1,AUC0～12h:(12·53±1·44)～(65·80±39·12)mU·h·mL-1;给药12周末的t1/2α:(0·68±0·48)～(1·18±0·83)h,cssmax:(1·92±0·79)～(8·62±1·51)mU·mL-1,AUC0～12h:(19·36±19·04)～(60·25±17·62)mU·h·mL-1,2时间点药动学参数比较无明显差异。结论:重组甘精胰岛素短时(给药6周)与长时(给药12周)给药的药动学参数未见明显差异。     

地黄寡糖在2型糖尿病大鼠模型上的降血糖作用及机制

目的研究地黄寡糖(ROS)在2型糖尿病(T2DM)动物模型和正常大鼠高血糖模型上对血糖的影响及机制。方法采用长期高脂肪饲料饲养加小剂量链脲佐菌素(STZ,30mg·kg-1,ip)诱导♀大鼠2型糖尿病动物模型;采用葡萄糖(2·5g·kg-1,ip)和肾上腺素(300μg·kg-1,ip)诱导正常♂大鼠高血糖模型。动物分为正常对照组、2型糖尿病模型组或高血糖模型组、ROS给药组及阳性对照二甲双胍组,以上各组均为灌胃给药。结果与2型糖尿病模型组比较,ROS高、低剂量组均可降低糖尿病大鼠的血糖值,以高剂量组最为明显;ROS对血浆总胆固醇(TC)、甘油三酯(TG)含量有降低趋势,对高密度脂蛋白胆固醇(HDL-C)含量有升高趋势;ROS可使肝脏葡萄糖-6-磷酸酶(G-6-Pase)活性降低,使肝糖原和胰岛素含量呈增加趋势;对正常大鼠肾上腺素性高血糖模型,ROS给药6d后,血糖峰值比高血糖模型组低。结论ROS灌胃给药对2型糖尿病大鼠的血糖有降低作用,其机制与降低肝葡萄糖-6-磷酸酶的活性有关,也可能与增加大鼠肝糖原合成和促进胰岛素分泌有关。ROS亦有降低大鼠肾上腺素性高血糖的作用。     

肥胖儿童伴黑棘皮病糖代谢特征及二甲双胍干预治疗58例

目的 :观察中、重度肥胖伴黑棘皮病病儿的糖代谢特征 ,二甲双胍干预治疗对糖、脂代谢的影响。方法 :选择中、重度肥胖病儿 5 8例 ,分为伴有黑棘皮病 (32例 )和不伴黑棘皮病 (2 6例 ) 2组 ,均予二甲双胍 5 0 0mg ,po ,bid× 8wk。结果 :(1)伴有黑棘皮病组治疗前空腹胰岛素 (FINS)为 (43±s 13)mU·L- 1、餐后 2h胰岛素 (PINS)为 (12 8± 2 3)mU·L- 1明显高于不伴黑棘皮病组 (30± 11)mU·L- 1,(5 8± 9)mU·L- 1(P <0 .0 1) ;(2 )二甲双胍干预治疗 8wk ,2组FINS ,PINS ,总胆固醇 (TC) ,三酰甘油 (TG) ,均有非常明显下降 (P <0 .0 1) ,胰岛素敏感指数 (IAI)上升 (P <0 .0 1) ,2组不良反应轻微。结论 :肥胖伴黑棘皮病病儿多存在高胰岛素血症、胰岛素抵抗 ,二甲双胍干预治疗能减轻胰岛素抵抗 ,增加机体对胰岛素的敏感性。     

Effect of yohimbine on urethane-induced hyperglycemia in rats

Urethane is a widely used anesthetic and yohimbine is a well-known alpha 2-adrenergic antagonist. In fasted Wistar rats urethane at an anesthetic dose (1.25 g/kg, i.p.) caused an increase in plasma glucose, while pentobarbital at an anesthetic dose (40 mg/kg, i.p.) did not. Urethane caused no change in plasma glucose in adrenalectomized rats. The hyperglycemic effect of urethane was not inhibited by pretreatment with propranolol (1 mg/kg, p.o.) or prazosin (10 mg/kg, p.o.), but was reduced by pretreatment with phentolamine (10 mg/kg, p.o.) or yohimbine (10 mg/kg, p.o.). Urethane caused an elevation of plasma adrenaline, and yohimbine reduced the elevation. In addition, the pretreatment of yohimbine potentiated the urethane-induced increase in plasma insulin. These results indicate that yohimbine may inhibit the urethane-induced hyperglycemia that is mediated by the central and peripheral alpha 2-adrenergic systems.     

饱和脂肪酸对AMPKa表达和活性的影响

目的探讨饱和脂肪酸对大鼠骨骼肌蛋白激酶(AMPKa)亚基表达及活性的影响,确定其在脂毒性发生中的地位和作用,为有效预防和控制脂毒性提供科学依据。方法雄性Wistar大鼠随机分为3组,每组10只,即对照组、高脂组和高脂加AMPKa激活剂组[二甲双胍50 mg/(kg.d),n=10]。喂养20周后,测定大鼠空腹和服糖后2 h血糖;用体外骨骼肌糖摄取试验评价大鼠骨骼肌胰岛素敏感性,Western blot法测定大鼠骨骼肌中AMPKa亚基和磷酸化AMPKa亚基蛋白水平。结果(1)与对照组比较,高脂组大鼠空腹血糖增加21.5%(P<0.05),服糖后2 h血糖增加28.3%(P<0.05),骨骼肌基础和胰岛素刺激后的糖摄取分别下降37.2%(P<0.05)和57.89%(P<0.01);(2)高脂组大鼠骨骼肌P-AMPKa和总AMPKa亚基蛋白水平分别下降46.1%(P<0.05)和79.4%(P<0.05);(3)与高脂组比较:二甲双胍显著上调AMPKa亚基的表达(P<0.05)和活性增加(P<0.05)。结论饱和脂肪酸通过降调AMPKa亚基表达和活性诱导大鼠胰岛素抵抗。     

Hypoglycemic activity of 1-alpha-(3,4-dimethoxyphenethylaminomethyl) -2-hydroxybenzylalcohol 1/2 fumarate (TA-078) in the mouse, rat and dog

1-alpha-(3,4-Dimethoxyphenethylaminomethyl)-2-hydroxybenzylalcohol 1/2 fumarate (TA-078) is a new hypoglycemic agent structurally different from any existing hypoglycemic drug. It depresses the rise of blood glucose when it is orally administered to glucose-loaded mice, rats and beagle dogs at minimal doses of 1, 10 and 2.5 mg/kg, respectively. In contrast with tolbutamide, TA-078 hardly affected fasting blood glucose levels in rats and dogs and only weakly reduced fasting blood glucose levels in mice. Oral administration of TA-078 to KK mice also improved glucose tolerance, while no improvement was observed in streptozotocin-diabetic rats. TA-078 elevated plasma immunoreactive insulin (IRI) levels in mice and rats soon after its oral administration. In fasted rats, TA-078 caused only a transient increase in plasma IRI but did not affect plasma immunoreactive glucagon (IRG) levels in the early phase after its administration. On the other hand, tolbutamide induced a sustained increase in plasma IRI and a transient but marked decrease in plasma IRG. In perfused rat pancreas, TA-078 stimulated insulin secretion. The stimulation by 10 micrograms/ml TA-078 in the perfusion liquid required the presence of a normal concn (5.6 mM) of glucose, whereas the same concn of tolbutamide stimulated insulin release even at a low glucose concn (2.8 mM).     

Metabolic changes induced by urethane-anesthesia in rats

1. Fasting hyperglycemia was observed in urethane-anesthetized rats. No significant changes had been observed in fed animals. The effect is dose-dependent, being ineffective doses lesser than 1.4 g/kg of body weight. 2. Urethane originates a rise in glycemia during the first 10 min of anesthesia followed by control values at 30 min, and a latter hyperglycemic phase for more than 60 min that remain at 2 hr. 3. The negative correlationship between plasma glucose, lactate and amino acid levels suggest that gluconeogenesis may be the main responsibility of the observed hyperglycemia during the first phase, but it is possible that during the second phase a decrease in the consumption of glucose may take place as a consequence of the competitive effects of ketone bodies increased during the first 30 min of anesthesia. 4. We postulate that the mechanism of the hyperglycemic response to urethane is a sympathetic response with release of catecholamines both in the liver and in the adrenal gland which enhances gluconeogenesis and lipolysis.     

Blockade of peripheral α2-adrenoceptors by L-659,066 enhances glucose tolerance and insulin release in mice

The purpose of this study was to compare the effects of a peripherally selective (L-659,066) vs. a centrally and peripherally active (L-657,743; MK-912) α₂-adrenergic antagonist on murine plasma glucose and insulin levels following fasting or administration of hyperglycemic agents (α₂-adrenergic agonists, glucose). The intravenous administration of L-657,743 or L-659,066 alone did not cause major alterations in plasma glucose or insulin levels. Pretreatment of mice with either of these agents, however, at selective α₂-adrenoceptor blocking doses (0.3–3 mg/kg) prevented the elevations of plasma glucose levels induced by the α₂-adrenoceptor agonists clonidine or 3,4-dihydroxyphenylimino-2-imidazoline (DPl). Prazosin, an α₁-adrenergic antagonist, did not alter clonidine-induced elevations of plasma glucose levels. Pretreatment of fasted mice with L-657,743 or L-659,066 (1 mg/kg) 5 min before receiving intravenous glucose resulted in higher plasma insulin levels and improved glucose tolerance compared to saline-pretreated animals. Moreover, both α₂-adrenergic antagonists enhanced the acute insulin response to glucose. These findings indicate that, under conditions of hyperglycemia, insulin release is enhanced by the blockade of peripheral α₂-adrenoceptors α₂-Adrenoceptor antagonists, such as L-657,743 or the peripherally selective agent L-659,066, may prove effective in treating noninsulin-dependent diabetes mellitus.     

Blockade of insulin release by certain phenothiazines

Chlorpromazine lowered the ratio of plasma insulin to blood glucose in adrenalectomized rats fed a glucose load. Desmethylchlorpromazine also lowered this ratio 30 min after glucose administration, but elevated it at 60 min. By contrast, fluphenazine had no significant effect on the ratio of plasma insulin to blood glucose. Chlorpromazine and desmethylchlorpromazine were more effective than fluphenazine in blocking insulin release from the isolated rat pancreas. Although adrenal epinephrine release and blockade of the effect of insulin may also be involved, the results of this study show that the hyperglycemic effect of certain phenothiazines is mainly determined by blockade of insulin release.     

Plasma glucose levels predict the disrupting effects of adrenoceptor antagonists on enhancement of memory storage.

Adrenoceptor antagonists block the enhancement of memory storage produced by epinephrine injection, but not that produced by glucose injection. The present experiment determined whether adrenoceptor antagonists modify resting blood glucose levels or the magnitude of epinephrine-, glucose-, and footshock-induced increases in circulating glucose levels in a manner related to these previously observed effects on memory. The alpha- and beta-adrenoceptor antagonists, phenoxybenzamine and propranolol, respectively, were injected in rats 30 min prior to administration of epinephrine, glucose, or footshock. Plasma glucose levels were sampled during the next 30 min. Epinephrine-induced increases in plasma glucose levels were potentiated by phenoxybenzamine and were attenuated and delayed by propranolol. The adrenoceptor antagonists did not alter resting plasma glucose levels, or the increases in plasma glucose levels resulting from glucose injection or footshock. These findings suggest that phenoxybenzamine and propranolol alter blood glucose responses to epinephrine injection in a manner which may contribute to attenuation of epinephrine-induced enhancement of memory storage with peripheral injections of adrenoceptor antagonists.     

高糖、高脂诱导大鼠肝脏胰岛素抵抗评价

目的:比较高糖、高脂等不同饮食诱导大鼠肝脏胰岛素抵抗模型的差异.方法:SD大鼠分成4组,分别给予普通、高糖、高脂、高糖高脂饲料,12周后检测各组空腹血糖水平、葡萄糖耐量、空腹血清胰岛素水平(FI)、胰岛素抵抗指数(HOMA-IR)、肝糖原含量及肝脏葡萄糖转运体2(GLUT2)、葡萄糖转运体4(GLUT4)表达水平.结果:口服糖耐量试验中,高脂组、高糖高脂组血糖曲线下面积分别为(91.6±5.5)和(106.1±4.6)mmol·min·L-1,较对照组明显增大(P<0.05或0.001).高脂组的FI与HOMA-IR分别为(20.2±0.9) μIU·L-1和(5.1±0.3),高糖高脂组则分别为(31.4±2.0) μIU·L-1 和(8.2±0.7),均较对照组显著升高(P<0.05或0.001).高糖高脂组的肝糖原含量为(1.3±0.0) mg·g-1,也较对照组显著增多(P<0.01).高脂组和高糖高脂组的GLUT2表达分别为(75.8±4.0)%和(60.0±4.5)%,均比对照组明显降低(P<0.05或0.001);高糖、高脂、高糖高脂组的GLUT4表达分别为(60.6±5.2)%,(72.3±3.8)%,(57.1±2.9)%,同样较对照组显著降低(P<0.001).结论:高糖结合高脂饮食更适合胰岛素抵抗模型的制备.